This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Petereit, H F Articles by Schoppe, S Search for Related Content PubMed PubMed Citation Articles by Petereit, H F Articles by Schoppe, S Social Bookmarking                         What's this?

Effect of immunomodulatory drugs on in vitro production of brain-derived neurotrophic factor

Department of Neurology, University of Cologne, D-50924 Cologne, Germany, hela.petereit{at}medizin.uni-koeln.de

H Lindemann

Department of Neurology, University of Cologne, D-50924 Cologne, Germany

S Schoppe

Department of Neurology, University of Cologne, D-50924 Cologne, Germany

Multiple sclerosis (MS), a disease of presumably autoimmune aetiology, is character ized by inflammation, demyelination and axonal degeneratio n in the central nervous system. C urrent treatment concepts target the inflammatory activity, reducing the number of relapses and inflammatory lesions on magnetic resonance imaging as well as the proinflammatory cytokine production in blood lymphocytes. Recently, the neuroprotective aspect of inflammation has been documented and is thought to be mediated by neurotrophins, like brain-derived neurotrophic factor (BDNF). The question whether the in vitro BDNF production in MS patients and healthy controls is influenced by the immunomodulatory agents interferon beta (IFN-beta) and immunoglobulin G (Ig) is addressed. A significantly increased BDNF production in MS patients was found compared with normal controls (mean±SD: 492±172 pg/mL versus 217±55 pg/mL, P-0.001). IFN-beta and low-dose Ig had no effect on BDNF production, whereas high-dose Ig reduced in vitro BDNF production in MS patients significantly (to 409±125 pg/mL, P-0.001). These in vitro findings might indicate that Igs in high doses potentially interfere with neuroprotective mechanisms despite their potent anti-inflammatory properties.

Key Words: brain-derived neurotrophic factor • immunoglobulin • immunomodulatory therapy • infl ammation • interferon beta • multiple sclerosis • neuroprotection

Multiple Sclerosis, Vol. 9, No. 1, 16-20 (2003)
DOI: 10.1191/1352458503ms869oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				K. Hamamcioglu and A. Reder Interferon-{beta} regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis Multiple Sclerosis, May 1, 2007; 13(4): 459 - 470. [Abstract] [PDF]

				P. Sarchielli, M. Zaffaroni, A. Floridi, L. Greco, A. Candeliere, A. Mattioni, S. Tenaglia, M. Di Filippo, and P. Calabresi Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-{beta} 1a, and high doses of immunoglobulins Multiple Sclerosis, April 1, 2007; 13(3): 313 - 331. [Abstract] [PDF]